US continues to monitor India-China disengagement process: State Dept

Price said, "We are closely following reports of troop disengagement and we welcome the ongoing efforts to deescalate the situation. We will continue to monitor the situation closely"

Ladakh
Tanks disengaging from the banks of Pangong lake area in Eastern Ladakh where they had been deployed opposite each other for almost ten months now. in Ladakh.
ANI US
2 min read Last Updated : Feb 23 2021 | 6:28 AM IST

After India and China completed their disengagement process in one part of border territory in Leh Ladakh, US State Department spokesperson Ned Price said that the United States welcomes the ongoing efforts to deescalate the situation and will continue to monitor the situation closely as both sides work toward a peaceful resolution.

At a press briefing, Price said, "We are closely following reports of troop disengagement and we welcome the ongoing efforts to deescalate the situation. We will continue to monitor the situation closely as both sides work toward a peaceful resolution."

When asked about India and US coordination on COVID-19 vaccines, Price said, "India and US build on decades of successful partnership and health and by the medical research, we are partnering to strengthen the global response to COVID-19."

"US and India recently welcomed an initiative to collaborate through an international center of excellence in research focused on infectious disease including Covid and we look forward to an overarching memorandum of understanding (MoU) to enhance health cooperation," he said.

Price further said that US and India are working together on developing diagnostics therapeutics vaccines to combat the disease and to recognise the importance of manufacturing critical drugs during this time and making them accessible globally.

"India's pharmaceutical sector is strong and well-established and has long played a central role in manufacturing life-saving vaccines for global use. We are pleased that the US pharmaceutical industry has been coordinating with the Indian pharma industry since the beginning of the COVID-19 pandemic," he added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Ladakh standoffAntony BlinkenIndia China border row

First Published: Feb 23 2021 | 6:18 AM IST

Next Story